Meta-analysis identifies common gut microbiota associated with multiple sclerosis.


Journal

Genome medicine
ISSN: 1756-994X
Titre abrégé: Genome Med
Pays: England
ID NLM: 101475844

Informations de publication

Date de publication:
31 Jul 2024
Historique:
received: 16 06 2023
accepted: 12 07 2024
medline: 1 8 2024
pubmed: 1 8 2024
entrez: 31 7 2024
Statut: epublish

Résumé

Previous studies have identified a diverse group of microbial taxa that differ between patients with multiple sclerosis (MS) and the healthy population. However, interpreting findings on MS-associated microbiota is challenging, as there is no true consensus. It is unclear whether there is gut microbiota commonly altered in MS across studies. To answer this, we performed a meta-analysis based on the 16S rRNA gene sequencing data from seven geographically and technically diverse studies comprising a total of 524 adult subjects (257 MS and 267 healthy controls). Analysis was conducted for each individual study after reprocessing the data and also by combining all data together. The blocked Wilcoxon rank-sum test and linear mixed-effects regression were used to identify differences in microbial composition and diversity between MS and healthy controls. Network analysis was conducted to identify bacterial correlations. A leave-one-out sensitivity analysis was performed to ensure the robustness of the findings. The microbiome community structure was significantly different between studies. Re-analysis of data from individual studies revealed a lower relative abundance of Prevotella in MS across studies, compared to controls. Meta-analysis found that although alpha and beta diversity did not differ between MS and controls, a higher abundance of Actinomyces and a lower abundance of Faecalibacterium were reproducibly associated with MS. Additionally, network analysis revealed that the recognized negative Bacteroides-Prevotella correlation in controls was disrupted in patients with MS. Our meta-analysis identified common gut microbiota associated with MS across geographically and technically diverse studies.

Sections du résumé

BACKGROUND BACKGROUND
Previous studies have identified a diverse group of microbial taxa that differ between patients with multiple sclerosis (MS) and the healthy population. However, interpreting findings on MS-associated microbiota is challenging, as there is no true consensus. It is unclear whether there is gut microbiota commonly altered in MS across studies.
METHODS METHODS
To answer this, we performed a meta-analysis based on the 16S rRNA gene sequencing data from seven geographically and technically diverse studies comprising a total of 524 adult subjects (257 MS and 267 healthy controls). Analysis was conducted for each individual study after reprocessing the data and also by combining all data together. The blocked Wilcoxon rank-sum test and linear mixed-effects regression were used to identify differences in microbial composition and diversity between MS and healthy controls. Network analysis was conducted to identify bacterial correlations. A leave-one-out sensitivity analysis was performed to ensure the robustness of the findings.
RESULTS RESULTS
The microbiome community structure was significantly different between studies. Re-analysis of data from individual studies revealed a lower relative abundance of Prevotella in MS across studies, compared to controls. Meta-analysis found that although alpha and beta diversity did not differ between MS and controls, a higher abundance of Actinomyces and a lower abundance of Faecalibacterium were reproducibly associated with MS. Additionally, network analysis revealed that the recognized negative Bacteroides-Prevotella correlation in controls was disrupted in patients with MS.
CONCLUSIONS CONCLUSIONS
Our meta-analysis identified common gut microbiota associated with MS across geographically and technically diverse studies.

Identifiants

pubmed: 39085949
doi: 10.1186/s13073-024-01364-x
pii: 10.1186/s13073-024-01364-x
doi:

Substances chimiques

RNA, Ribosomal, 16S 0

Types de publication

Journal Article Meta-Analysis

Langues

eng

Sous-ensembles de citation

IM

Pagination

94

Subventions

Organisme : NIH HHS
ID : R01 NS102633
Pays : United States

Informations de copyright

© 2024. The Author(s).

Références

Mirza A, Forbes JD, Zhu F, Bernstein CN, Van Domselaar G, Graham M, Waubant E, Tremlett H. The multiple sclerosis gut microbiota: a systematic review. Mult Scler Relat Disord. 2020;37:101427.
pubmed: 32172998 doi: 10.1016/j.msard.2019.101427
Cantoni C, Lin Q, Dorsett Y, Ghezzi L, Liu Z, Pan Y, Chen K, Han Y, Li Z, Xiao H, et al. Alterations of host-gut microbiome interactions in multiple sclerosis. EBioMedicine. 2022;76:103798.
pubmed: 35094961 pmcid: 8814376 doi: 10.1016/j.ebiom.2021.103798
Katz Sand I, Zhu Y, Ntranos A, Clemente JC, Cekanaviciute E, Brandstadter R, Crabtree-Hartman E, Singh S, Bencosme Y, Debelius J, et al. Disease-modifying therapies alter gut microbial composition in MS. Neurol Neuroimmunol Neuroinflamm. 2019;6:e517.
pubmed: 30568995 doi: 10.1212/NXI.0000000000000517
Cekanaviciute E, Yoo BB, Runia TF, Debelius JW, Singh S, Nelson CA, Kanner R, Bencosme Y, Lee YK, Hauser SL, et al. Gut bacteria from multiple sclerosis patients modulate human T cells and exacerbate symptoms in mouse models. Proc Natl Acad Sci U S A. 2017;114:10713–8.
pubmed: 28893978 pmcid: 5635915 doi: 10.1073/pnas.1711235114
Chen J, Chia N, Kalari KR, Yao JZ, Novotna M, Paz Soldan MM, Luckey DH, Marietta EV, Jeraldo PR, Chen X, et al. Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Sci Rep. 2016;6:28484.
pubmed: 27346372 pmcid: 4921909 doi: 10.1038/srep28484
Choileain SN, Kleinewietfeld M, Raddassi K, Hafler DA, Ruff WE, Longbrake EE. CXCR3+ T cells in multiple sclerosis correlate with reduced diversity of the gut microbiome. J Transl Autoimmun. 2020;3:100032.
pubmed: 32743517 doi: 10.1016/j.jtauto.2019.100032
Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, et al. Alterations of the human gut microbiome in multiple sclerosis. Nat Commun. 2016;7:12015.
pubmed: 27352007 pmcid: 4931233 doi: 10.1038/ncomms12015
Miyake S, Kim S, Suda W, Oshima K, Nakamura M, Matsuoka T, Chihara N, Tomita A, Sato W, Kim SW, et al. Dysbiosis in the gut microbiota of patients with multiple sclerosis, with a striking depletion of species belonging to Clostridia XIVa and IV clusters. PLoS One. 2015;10:e0137429.
pubmed: 26367776 pmcid: 4569432 doi: 10.1371/journal.pone.0137429
Tremlett H, Zhu F, Arnold D, Bar-Or A, Bernstein CN, Bonner C, Forbes JD, Graham M, Hart J, Knox NC, et al. The gut microbiota in pediatric multiple sclerosis and demyelinating syndromes. Ann Clin Transl Neurol. 2021;8:2252–69.
pubmed: 34889081 pmcid: 8670321 doi: 10.1002/acn3.51476
Tremlett H, Fadrosh DW, Faruqi AA, Zhu F, Hart J, Roalstad S, Graves J, Lynch S, Waubant E. Centers USNoPM: Gut microbiota in early pediatric multiple sclerosis: a case-control study. Eur J Neurol. 2016;23:1308–21.
pubmed: 27176462 doi: 10.1111/ene.13026
Zeng Q, Junli G, Liu X, Chen C, Sun X, Li H, Zhou Y, Cui C, Wang Y, Yang Y, et al. Gut dysbiosis and lack of short chain fatty acids in a Chinese cohort of patients with multiple sclerosis. Neurochem Int. 2019;129:104468.
pubmed: 31108132 doi: 10.1016/j.neuint.2019.104468
Berer K, Gerdes LA, Cekanaviciute E, Jia X, Xiao L, Xia Z, Liu C, Klotz L, Stauffer U, Baranzini SE, et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S A. 2017;114:10719–24.
pubmed: 28893994 pmcid: 5635914 doi: 10.1073/pnas.1711233114
Swidsinski A, Dorffel Y, Loening-Baucke V, Gille C, Goktas O, Reisshauer A, Neuhaus J, Weylandt KH, Guschin A, Bock M. Reduced mass and diversity of the colonic microbiome in patients with multiple sclerosis and their improvement with ketogenic diet. Front Microbiol. 2017;8:1141.
pubmed: 28702003 pmcid: 5488402 doi: 10.3389/fmicb.2017.01141
Reynders T, Devolder L, Valles-Colomer M, Van Remoortel A, Joossens M, De Keyser J, Nagels G, D’Hooghe M, Raes J. Gut microbiome variation is associated to Multiple Sclerosis phenotypic subtypes. Ann Clin Transl Neurol. 2020;7:406–19.
pubmed: 32162850 pmcid: 7187717 doi: 10.1002/acn3.51004
Forbes JD, Chen CY, Knox NC, Marrie RA, El-Gabalawy H, de Kievit T, Alfa M, Bernstein CN, Van Domselaar G. A comparative study of the gut microbiota in immune-mediated inflammatory diseases-does a common dysbiosis exist? Microbiome. 2018;6:221.
pubmed: 30545401 pmcid: 6292067 doi: 10.1186/s40168-018-0603-4
Tankou SK, Regev K, Healy BC, Tjon E, Laghi L, Cox LM, Kivisakk P, Pierre IV, Hrishikesh L, Gandhi R, et al. A probiotic modulates the microbiome and immunity in multiple sclerosis. Ann Neurol. 2018;83:1147–61.
pubmed: 29679417 pmcid: 6181139 doi: 10.1002/ana.25244
Kozhieva M, Naumova N, Alikina T, Boyko A, Vlassov V, Kabilov MR. Primary progressive multiple sclerosis in a Russian cohort: relationship with gut bacterial diversity. BMC Microbiol. 2019;19:309.
pubmed: 31888483 pmcid: 6937728 doi: 10.1186/s12866-019-1685-2
Teng F, Darveekaran Nair SS, Zhu P, Li S, Huang S, Li X, Xu J, Yang F. Impact of DNA extraction method and targeted 16S-rRNA hypervariable region on oral microbiota profiling. Sci Rep. 2018;8:16321.
pubmed: 30397210 pmcid: 6218491 doi: 10.1038/s41598-018-34294-x
Duvallet C, Gibbons SM, Gurry T, Irizarry RA, Alm EJ. Meta-analysis of gut microbiome studies identifies disease-specific and shared responses. Nat Commun. 2017;8:1784.
pubmed: 29209090 pmcid: 5716994 doi: 10.1038/s41467-017-01973-8
Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: high-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13:581–3.
pubmed: 27214047 pmcid: 4927377 doi: 10.1038/nmeth.3869
Bolger AM, Lohse M, Usadel B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014;30:2114–20.
pubmed: 24695404 pmcid: 4103590 doi: 10.1093/bioinformatics/btu170
Rognes T, Flouri T, Nichols B, Quince C, Mahe F. VSEARCH: a versatile open source tool for metagenomics. PeerJ. 2016;4:e2584.
pubmed: 27781170 pmcid: 5075697 doi: 10.7717/peerj.2584
Nearing JT, Douglas GM, Hayes MG, MacDonald J, Desai DK, Allward N, Jones CMA, Wright RJ, Dhanani AS, Comeau AM, Langille MGI. Microbiome differential abundance methods produce different results across 38 datasets. Nat Commun. 2022;13:342.
pubmed: 35039521 pmcid: 8763921 doi: 10.1038/s41467-022-28034-z
Li Y, Ge X, Peng F, Li W, Li JJ. Exaggerated false positives by popular differential expression methods when analyzing human population samples. Genome Biol. 2022;23:79.
pubmed: 35292087 pmcid: 8922736 doi: 10.1186/s13059-022-02648-4
Shah S, Locca A, Dorsett Y, Cantoni C, Ghezzi L, Lin Q, Bokoliya S, Panier H, Suther C, Gormley M, et al. Alterations of the gut mycobiome in patients with MS. EBioMedicine. 2021;71:103557.
pubmed: 34455391 pmcid: 8399064 doi: 10.1016/j.ebiom.2021.103557
Wirbel J, Pyl PT, Kartal E, Zych K, Kashani A, Milanese A, Fleck JS, Voigt AY, Palleja A, Ponnudurai R, et al. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med. 2019;25:679–89.
pubmed: 30936547 pmcid: 7984229 doi: 10.1038/s41591-019-0406-6
Sheu CF, Suzuki S. Meta-analysis using linear mixed models. Behav Res Methods Instrum Comput. 2001;33:102–7.
pubmed: 11447661 doi: 10.3758/BF03195354
Pasolli E, Truong DT, Malik F, Waldron L, Segata N. Machine learning meta-analysis of large metagenomic datasets: tools and biological insights. PLoS Comput Biol. 2016;12:e1004977.
pubmed: 27400279 pmcid: 4939962 doi: 10.1371/journal.pcbi.1004977
Faust K, Sathirapongsasuti JF, Izard J, Segata N, Gevers D, Raes J, Huttenhower C. Microbial co-occurrence relationships in the human microbiome. PLoS Comput Biol. 2012;8:e1002606.
pubmed: 22807668 pmcid: 3395616 doi: 10.1371/journal.pcbi.1002606
Friedman J, Alm EJ. Inferring correlation networks from genomic survey data. PLoS Comput Biol. 2012;8:e1002687.
pubmed: 23028285 pmcid: 3447976 doi: 10.1371/journal.pcbi.1002687
Riviere A, Selak M, Lantin D, Leroy F, De Vuyst L. Bifidobacteria and butyrate-producing colon bacteria: importance and strategies for their stimulation in the human gut. Front Microbiol. 2016;7:979.
pubmed: 27446020 pmcid: 4923077 doi: 10.3389/fmicb.2016.00979
Gorvitovskaia A, Holmes SP, Huse SM. Interpreting Prevotella and Bacteroides as biomarkers of diet and lifestyle. Microbiome. 2016;4:15.
pubmed: 27068581 pmcid: 4828855 doi: 10.1186/s40168-016-0160-7
Roager HM, Licht TR, Poulsen SK, Larsen TM, Bahl MI. Microbial enterotypes, inferred by the prevotella-to-bacteroides ratio, remained stable during a 6-month randomized controlled diet intervention with the new nordic diet. Appl Environ Microbiol. 2014;80:1142–9.
pubmed: 24296500 pmcid: 3911217 doi: 10.1128/AEM.03549-13
Zhou X, Baumann R, Gao X, Mendoza M, Singh S, Katz Sand I, Xia Z, et al. Gut microbiome of multiple sclerosis patients and paired household healthy controls reveal associations with disease risk and course. Cell. 2022;185(19):3467-86.
Zhou Y, Mihindukulasuriya KA, Gao H, La Rosa PS, Wylie KM, Martin JC, Kota K, Shannon WD, Mitreva M, Sodergren E, Weinstock GM. Exploration of bacterial community classes in major human habitats. Genome Biol. 2014;15:R66.
pubmed: 24887286 pmcid: 4073010 doi: 10.1186/gb-2014-15-5-r66
Shahi SK, Freedman SN, Murra AC, Zarei K, Sompallae R, Gibson-Corley KN, Karandikar NJ, Murray JA, Mangalam AK. Prevotella histicola, a human gut commensal, is as potent as COPAXONE(R) in an animal model of multiple sclerosis. Front Immunol. 2019;10:462.
pubmed: 30984162 pmcid: 6448018 doi: 10.3389/fimmu.2019.00462
Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174–80.
pubmed: 21508958 pmcid: 3728647 doi: 10.1038/nature09944
Manor O, Dai CL, Kornilov SA, Smith B, Price ND, Lovejoy JC, Gibbons SM, Magis AT. Health and disease markers correlate with gut microbiome composition across thousands of people. Nat Commun. 2020;11:5206.
pubmed: 33060586 pmcid: 7562722 doi: 10.1038/s41467-020-18871-1
Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Dore J. Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis. 2009;15:1183–9.
pubmed: 19235886 doi: 10.1002/ibd.20903
Ueda A, Shinkai S, Shiroma H, Taniguchi Y, Tsuchida S, Kariya T, Kawahara T, Kobayashi Y, Kohda N, Ushida K, et al. Identification of Faecalibacterium prausnitzii strains for gut microbiome-based intervention in Alzheimer’s-type dementia. Cell Rep Med. 2021;2:100398.
pubmed: 34622235 pmcid: 8484692 doi: 10.1016/j.xcrm.2021.100398
Stopinska K, Radziwon-Zaleska M, Domitrz I. The microbiota-gut-brain axis as a key to neuropsychiatric disorders: a mini review. J Clin Med. 2021;10(20):4640.
pubmed: 34682763 pmcid: 8539144 doi: 10.3390/jcm10204640
Cosorich I, Dalla-Costa G, Sorini C, Ferrarese R, Messina MJ, Dolpady J, Radice E, Mariani A, Testoni PA, Canducci F, et al. High frequency of intestinal T(H)17 cells correlates with microbiota alterations and disease activity in multiple sclerosis. Sci Adv. 2017;3:e1700492.
pubmed: 28706993 pmcid: 5507635 doi: 10.1126/sciadv.1700492
Chirouze C, Patry I, Duval X, Baty V, Tattevin P, Aparicio T, Pagenault M, Carbonnel F, Couetdic G, Hoen B. Streptococcus bovis/Streptococcus equinus complex fecal carriage, colorectal carcinoma, and infective endocarditis: a new appraisal of a complex connection. Eur J Clin Microbiol Infect Dis. 2013;32:1171–6.
pubmed: 23558362 doi: 10.1007/s10096-013-1863-3
Teitelbaum JE, Triantafyllopoulou M. Inflammatory bowel disease and Streptococcus bovis. Dig Dis Sci. 2006;51:1439–42.
pubmed: 16868828 doi: 10.1007/s10620-005-9053-5
Topkaya AE, Sahin S, Aksungar FB, Boru UT, Yildiz Z, Sur H. Is there any relationship between streptococcal infection and multiple sclerosis? Med Sci Monit. 2007;13:CR567-569.
pubmed: 18049437
Herrmann I, Kellert M, Schmidt H, Mildner A, Hanisch UK, Bruck W, Prinz M, Nau R. Streptococcus pneumoniae infection aggravates experimental autoimmune encephalomyelitis via Toll-like receptor 2. Infect Immun. 2006;74:4841–8.
pubmed: 16861672 pmcid: 1539614 doi: 10.1128/IAI.00026-06
Kitamoto S, Nagao-Kitamoto H, Jiao Y, Gillilland MG 3rd, Hayashi A, Imai J, Sugihara K, Miyoshi M, Brazil JC, Kuffa P, et al. The intermucosal connection between the mouth and gut in commensal pathobiont-driven colitis. Cell. 2020;182(447–462):e414.
Lin Q, Dorsett Y, Mirza A, Tremlett H, Piccio L, Longbrake EE, Ni Choileain S, Hafler DA, Cox LM, Weiner HL, Yamamura T, Chen K, Wu Y, Zhou Y. Meta-analysis for MS. GitHub. https://github.com/YZhouLabUConnHealth/meta_analysis_MS (2024).

Auteurs

Qingqi Lin (Q)

Department of Computer Science and Engineering, University of Connecticut, Storrs, CT, USA.
Department of Medicine, University of Connecticut Health Center, Farmington, CT, USA.

Yair Dorsett (Y)

Department of Medicine, University of Connecticut Health Center, Farmington, CT, USA.

Ali Mirza (A)

Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.

Helen Tremlett (H)

Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.

Laura Piccio (L)

Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.
Brain and Mind Centre, School of Medical Sciences, University of Sydney, Sydney, New South Wales, Australia.

Erin E Longbrake (EE)

Departments of Neurology and Immunobiology, Yale University School of Medicine, New Haven, CT, 06511, USA.

Siobhan Ni Choileain (SN)

Departments of Neurology and Immunobiology, Yale University School of Medicine, New Haven, CT, 06511, USA.

David A Hafler (DA)

Departments of Neurology and Immunobiology, Yale University School of Medicine, New Haven, CT, 06511, USA.

Laura M Cox (LM)

Ann Romney Center for Neurologic Diseases, Harvard Medical School, Brigham & Women's Hospital, Boston, MA, 02115, USA.

Howard L Weiner (HL)

Ann Romney Center for Neurologic Diseases, Harvard Medical School, Brigham & Women's Hospital, Boston, MA, 02115, USA.

Takashi Yamamura (T)

Department of Immunology, National Institute of Neuroscience, Tokyo, Japan.

Kun Chen (K)

Department of Statistics, University of Connecticut, Storrs, CT, USA.

Yufeng Wu (Y)

Department of Computer Science and Engineering, University of Connecticut, Storrs, CT, USA.

Yanjiao Zhou (Y)

Department of Medicine, University of Connecticut Health Center, Farmington, CT, USA. yazhou@uchc.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH